Aberrant function of the Ras signal transduction pathway in human breast cancer

Breast Cancer Research and Treatment

Volumn 35, Issue 1, 1995, Pages 133-144

  Clark, Geoffrey J ^a   Der, Channing J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

oncogenes; ras oncogene; Ras related proteins; rational drug design; signal transduction pathways

Indexed keywords

CELL SURFACE RECEPTOR; GLYCOPROTEIN GP 140;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER GROWTH; CELL DIFFERENTIATION; GENE MUTATION; GROWTH REGULATION; HUMAN; MALIGNANT TRANSFORMATION; ONCOGENE RAS; PRIORITY JOURNAL; PROTO ONCOGENE; SIGNAL TRANSDUCTION;

APOPTOSIS; BREAST NEOPLASMS; GENES, RAS; HUMAN; MUTATION; PROTO-ONCOGENE PROTEIN P21(RAS); SIGNAL TRANSDUCTION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029002907     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/BF00694753     Document Type: Article

References (106)

1. The GTPase superfamily: a conserved switch for diverse cell functions
2. The GTPase superfamily: conserved structure and molecular mechanism
3. Proteins regulating Ras and its relatives
4. Non-nuclear oncogenes and the regulation of gene expression in transformed cells
5. Regulatory mechanisms for ras proteins
6. Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus
7. ras genes
8. ras oncogenes in human cancer: a review
9. Oncogenic activation of Ras proteins
10. ras oncogenes in chemical carcinogenesis
11. 17β-estradiol regulates and v-Ha-ras transfection constitutively enhances MCF7 breast cancer cell interactions with basement membrane
12. Independent molecular pathways in initiation and loss of hormone responsiveness of breast carcinomas
13. Transformation of human breast epithelial cells by c-Ha- ras oncogene
14. Coexpression of MMTV/v-Ha- ras and MMTV/c- myc genes in transgenic mice: synergistic action of oncogenes in vivo
15. Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas
16. Oncogene activation in malignant transformation: a study of H- ras in human breast cancer
17. Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 in human breast cancer
18. The Ras signal transduction pathway
19. Pathways of Ras function: connections to the actin cytoskeleton
20. The mitogen-activated protein kinase signal transduction pathway
21. The molecular genetics of cancer
22. Molecular themes in oncogenesis
23. Oncogenes and signal transduction
24. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells
25. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae
26. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21
27. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins
28. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis
29. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients
30. Membrane-targeting potentiates guanine nucleotide exchange factor CDC25 and SOS1 activation of Ras transforming activity
31. The Saccharomyces cerevisiae gene product SDC25 C-domain functions as an oncoprotein in NIH3T3 cells
32. Regulated and constitutive activity by CDC25Mm (GRF), a ras-specific exchange factor
33. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation
34. Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: relationship to estrogen receptor and lymphatic invasion
35. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer
36. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene
37. How receptors turn Ras on
38. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins
39. Signalling through SH2 and SH3 domains
40. SH2 and SH3 domains
41. SH2 domains recognize specific phosphopeptide sequences
42. Structural basis for the binding of proline-rich peptides to SH3 domains
43. Triggering signaling cascades by receptor tyrosine kinases
44. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway
45. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein
46. Multiple BCR-related gene products and their proposed involvement in ligand-induced signal transduction pathways
47. ras and GAP — who's controlling whom?
48. Ras p21: effects and regulation
49. A signal chain of events
50. Differential antagonism of Ras biological activity by catalytic and Src homology domains of Ras GTPase activation protein
51. Identification of the SH3 domain of GAP as an essential sequence for Ras-GAP-mediated signaling
52. GAP domains responsible for ras p21-dependent inhibition of muscarinic atrial K+ channel currents
53. Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function
54. Nonsense mutations in the C-terminal SH2 region of the GTPase activating protein (GAP) gene in human tumors
55. Complexes of Ras-GTP with Raf-1 and mitogen-activated protein kinase
56. Complex formation between RAS and RAF and other protein kinases
57. Vojtek AB, Hollenberg SM, Cooper JA: Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 205–214, 1993
58. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1
59. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro
60. Activation of Raf as a result of recruitment to the plasma membrane
61. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
62. MAP kinase regulation — the oncogene connection
63. Extracellular signals and reversible protein phosphorylation: what to mek of it all
64. Signal transduction via the MAP kinases: proceed at your own RSK
65. Sequential protein kinase reactions controlling cell growth and differentiation
66. Activation of human raf transforming genes by deletion of normal aminoterminal coding sequences
67. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase
68. A gain-of-function mutation in Drosophila MAP kinase activates multiple receptor tyrosine kinase signaling pathways
69. Emerging concepts in the Ras superfamily of GTP-binding proteins
70. Small GTP-binding proteins and their role in transport
71. Ras-related GTPases and the cytoskeleton
72. Mitotic regulator protein RCC1 is complexed with a nuclear ras-related polypeptide
73. The GTP-binding protein Ran/TC4 is required for protein import into the nucleus
74. Ran/TC4: a small nuclear GTP-binding protein that regulates DNA synthesis
75. Aberrant function of the Ras-related TC21/R-Ras2 protein triggers malignant transformation
76. R-Ras induces malignant, but not morphologic, transformation of NIH 3T3 cells
77. Characterization of four novel ras-like genes expressed in a human teratocarcinoma cell line
78. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10
79. R-ras interacts with rasGAP, neurofibromin, and c- raf but does not regulate cell growth or differentiation
80. Bc1-2 associates with the ras-related protein R- ras p23
81. Ras C-terminal processing enzymes — new drug targets
82. Protein prenylation: key to ras function and cancer intervention?
83. Anti-Ras drugs come of age
84. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues
85. Protein prenylation and associated modifications
86. Protein prenylation: more than just glue?
87. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity
88. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides
89. Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase
90. Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase
91. Identification of geranylgeranyl-modified proteins in HeLa cells
92. Quantitation of prenylcysteines by a selective cleavage reaction
93. Biochemistry of protein prenylation
94. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells
95. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
96. Peptidomimetic inhibitors of ras farnesylation and function in whole cells
97. Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21rasCA1A2X peptidomimetics
98. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic Ras signaling and transformation
99. A putative modular domain present in diverse signaling proteins
100. The PH domain: a common piece in the structural patchwork of signaling proteins
101. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells
102. Oncogenic Ras activates c-Jun via a separate pathway from the activation of extra-cellular-signal regulated kinases
103. Inhibition of Fos-and Ras-induced transformation by mutant Fos proteins with structural alterations in functionally different domains
104. Transformation and transactivation suppressor activity of the c-Jun leucine zipper fused to a bacterial repressor
105. Mitogenic signaling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression